An interventional study of Aminoguanidine and Placebos in Chronic Obstructive Pulmonary Disease, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-10.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, induced sputum, nasal lavage and mouth wash fluid in healthy non-smokers, current smokers and patients with COPD.
Nitric oxide (NO) is produced by resident and inflammatory cells in the respiratory tract by the enzyme NO synthase (NOS), which exists in three isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS. NO production is increased in patients with COPD, and the production of NO under oxidative stress conditions generates reactive nitrogen species that may amplify the inflammatory response in COPD.
2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.
This study's enrollment of 30 is below the median of 66 across 1,837 interventional studies indexed under Lung Diseases, Obstructive.
Browse Lung Diseases, Obstructive studies →Imperial College London is the lead sponsor of 824 studies on the registry; 178 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
At risk (current smokers)
Moderate COPD
Exclusion Criteria:
Control group
Drug: Aminoguanidine · Drug: Placebos
More than 10 pack-years
Drug: Aminoguanidine · Drug: Placebos
COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
Drug: Aminoguanidine · Drug: Placebos
500mg
Also known as: Nebulased Aminoguanidine
2ml
Also known as: Nebulase saline solution
Bronchial exhale nitric oxide (JNO)
Bronchial exhale nitric oxide (JNO) as assessed by Chemo luminescence
Time frame: 24 hours
Plan to share: No
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College London